Inactive Instrument

Zynerba Pharmaceuticals, Inc.

Equities

ZYNE

US98986X1090

Biotechnology & Medical Research

ZYNERBA PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

January 09, 2023 at 07:35 am

Item 8.01 Other Events

Attached as Exhibit 99.1 is a presentation, including certain financial information, that Zynerba Pharmaceuticals, Inc. will post on its website on January 9, 2023, and may use from time to time in presentations or discussions with investors, analysts, or other parties.

Item 9.01 Financial Statements and Exhibits

The following exhibits are being filed herewith:





(d) Exhibits



Exhibit
No.                                       Document
  99.1       Zynerba Pharmaceuticals, Inc. Presentation
104        The cover page from this Current Report on Form 8-K, formatted in
           Inline XBRL

Latest news about Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.	04-29	CI
Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index	23-10-12	CI
Harmony Biosciences Holdings Completes Acquisition of Zynerba Pharmaceuticals	23-10-11	MT
Harmony Biosciences Holdings, Inc. completed the acquisition of Zynerba Pharmaceuticals, Inc..	23-10-09	CI
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index	23-09-28	CI
Harmony Biosciences Says its Xylophone Acquisition Unit Extends Tender Offer for Zynerba Pharmaceuticals to Oct. 10	23-09-27	MT
North American Morning Briefing : Treasury Yields -2-	23-08-17	DJ
Canaccord Genuity Downgrades Zynerba Pharmaceuticals to Hold From Buy, Adjusts Price Target to $1.11 From $10	23-08-16	MT
North American Morning Briefing : Stock Futures -2-	23-08-16	DJ
HC Wainwright Downgrades Zynerba Pharmaceuticals to Neutral From Buy	23-08-15	MT
Health Care Up on Drug Developments -- Health Care Roundup	23-08-14	DJ
Sector Update: Health Care Stocks Higher Late Afternoon	23-08-14	MT
Sector Update: Health Care Stocks Higher on Monday Afternoon	23-08-14	MT
Top Midday Gainers	23-08-14	MT
Zynerba Pharmaceuticals Shares Soar on Harmony Biosciences Acquisition Deal	23-08-14	MT
Sector Update: Health Care Stocks Edge Higher Premarket Monday	23-08-14	MT
Sector Update: Health Care	23-08-14	MT
Transcript : Harmony Biosciences Holdings, Inc., Zynerba Pharmaceuticals, Inc. - M&A Call	23-08-14
Harmony Biosciences Agrees to Acquire Zynerba Pharmaceuticals	23-08-14	MT
Harmony Biosciences To Acquire Zynerba Pharmaceuticals, Inc.	23-08-14	RE
Zynerba Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Harmony Biosciences Holdings, Inc. entered into a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. ) for $63.7 million.	23-08-13	CI
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from Russell Microcap Value Index	23-06-23	CI
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from Russell 3000E Value Index	23-06-23	CI
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from Russell 3000E Index	23-06-23	CI

Chart Zynerba Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 deletion syndrome (22q). It is focused on using cannabinoids for treating behavioral symptoms of FXS and 22q. The Company is developing Zygel (ZYN002), a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol (THC). It uses a patent protected formulation containing ethanol and propylene glycol as solubilizing agents and Transcutol HP as a permeation enhancer. Zygel is an investigational drug product in development for the potential treatment of behavioral symptoms associated with FXS, 22q, and autism spectrum disorder (ASD).

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+22.30%	47.96B
IQVIA HOLDINGS INC.	+0.83%	42.45B
LONZA GROUP AG	+43.91%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+27.04%	31.6B
ICON PUBLIC LIMITED COMPANY	+21.26%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+52.55%	14.56B
MEDPACE HOLDINGS, INC.	+44.78%	14.14B
BIO-TECHNE CORPORATION	+3.05%	12.58B

Other Biotechnology & Medical Research